Pages that link to "Q46503339"

The following pages link to PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients (Q46503339):

Displaying 43 items.

• Optimisation of whole-body PET/CT scanning protocols (Q28744472) (← links)
• Evaluation of Dixon Sequence on Hybrid PET/MR Compared with Contrast-Enhanced PET/CT for PET-Positive Lesions (Q30829156) (← links)
• Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data (Q33710688) (← links)
• Methodological considerations in quantification of oncological FDG PET studies. (Q33915164) (← links)
• Semi-Quantitative Calculations of Primary Tumor Metabolic Activity Using F-18 FDG PET/CT as a Predictor of Survival in 92 Patients With High-Grade Bone or Soft Tissue Sarcoma (Q36196581) (← links)
• Volume-Based F-18 FDG PET/CT Imaging Markers Provide Supplemental Prognostic Information to Histologic Grading in Patients With High-Grade Bone or Soft Tissue Sarcoma (Q36421044) (← links)
• Monitoring chemotherapy and radiotherapy of solid tumors (Q36474962) (← links)
• Multi-modality nuclear medicine imaging: artefacts, pitfalls and recommendations (Q36834532) (← links)
• PET/CT imaging: what radiologists need to know (Q36963769) (← links)
• Quality assurance of positron emission tomography/computed tomography for radiation therapy (Q37011261) (← links)
• Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. (Q37240835) (← links)
• PET-CT in oncology: making the most of CT (Q37292842) (← links)
• Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma (Q37326204) (← links)
• PET/CT in radiation oncology (Q37345402) (← links)
• Diagnostic and therapeutic imaging for cancer: Therapeutic considerations and future directions (Q37863631) (← links)
• Single photon emission tomography/computed tomography (SPET/CT) and positron emission tomography/computed tomography (PET/CT) to image cancer. (Q37863633) (← links)
• Intravenous contrast-enhanced CT can be used for CT-based attenuation correction in clinical (111)In-octreotide SPECT/CT. (Q40392465) (← links)
• Contrast-enhanced small-animal PET/CT in cancer research: strong improvement of diagnostic accuracy without significant alteration of quantitative accuracy and NEMA NU 4-2008 image quality parameters (Q41781081) (← links)
• Accuracy of CT-based attenuation correction in PET/CT bone imaging (Q42172418) (← links)
• How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting (Q43529305) (← links)
• Multiphase contrast-enhanced CT with highly concentrated contrast agent can be used for PET attenuation correction in integrated PET/CT imaging (Q43988491) (← links)
• Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer (Q45038526) (← links)
• Role of PET/CT in the detection of liver metastases from colorectal cancer. (Q46010928) (← links)
• Diagnostic value of PET/CT for the staging and restaging of pediatric tumors (Q46416802) (← links)
• The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials (Q46428527) (← links)
• PET/CT in lung cancer: Influence of contrast medium on quantitative and clinical assessment (Q47669163) (← links)
• Quantitative analysis shows that contrast medium in positron emission tomography/computed tomography may cause significant artefacts (Q47956398) (← links)
• Quantitative effects of contrast enhanced CT attenuation correction on PET SUV measurements (Q48014123) (← links)
• Operational and Dosimetric Aspects of Pediatric PET/CT. (Q50541148) (← links)
• Assessment of errors caused by X-ray scatter and use of contrast medium when using CT-based attenuation correction in PET. (Q51223572) (← links)
• Correction of oral contrast artifacts in CT-based attenuation correction of PET images using an automated segmentation algorithm (Q51888323) (← links)
• Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. (Q52767151) (← links)
• Quantifying the effects of iodine contrast media on standardised uptake values of FDG PET/CT images: an anthropomorphic phantom study (Q53211536) (← links)
• Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. (Q53293104) (← links)
• The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. (Q53483471) (← links)
• Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer (Q57780606) (← links)
• PET/CT in head and neck cancer (Q62096580) (← links)
• Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer (Q80079357) (← links)
• Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer (Q80685832) (← links)
• Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? (Q80786431) (← links)
• The diagnostic and prognostic value of ¹⁸F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients (Q84379718) (← links)
• Impact of acquisition time and penalizing factor in a block-sequential regularized expectation maximization reconstruction algorithm on a Si-photomultiplier-based PET-CT system for 18F-FDG (Q92161043) (← links)
• What and how should we measure in paediatric oncology FDG-PET/CT? Comparison of commonly used SUV metrics for differentiation between paediatric tumours (Q92224671) (← links)